Within the Human Protein Atlas project, antibodies are used to study the localization of protein in human tissues and cells. To generate the antibodies recombinant expression clones are produced from human RNA pools by cDNA synthesis, cloning and plasmid purification. These clones produce what is called Protein Epitope Signature Tags (PrESTs), a selected part of the target protein that should be recognized by antibodies.

Johan Rockberg, Associate Professor in antibody technology and directed evolution at KTH - Royal Institute of Technology in Stockholm, Sweden is the group leader for the epitope mapping and therapeutic antibodies group within the Human Protein Atlas...Read more

The term precision medicine describes the idea of providing effective treatment based on a patient´s molecular make up.

Eculizumab is used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS). However, eculizumab is a very expensive drug, and the treatment is not efficient for all patients...Read more

In a paper published in Nature Scientific Reports last week, researchers from the Human Protein Atlas describe a method for stratification of responders towards the drug eculizumab that allows for precision medicine and should be applicable to several other diseases and therapeutics.

The term precision medicine describes the idea of providing effective treatment based on a patient´s molecular make up. Recent advances in molecular diagnostic tools and handling of large data sets allow for the stratification of patients based on e.g. genetic or protein information and make it possible to provide tailored treatment for these sub-groups...Read more